Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection

Bibliography

• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Gasbarrini A, Pompili M, et al. Management of hepatitis C virus infection recurrence after liver transplantation: an overview. Transplant Proc 2011;43:291-5
   PubMed Web of Science ®Google Scholar
• Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011;6:478-82
   PubMed Web of Science ®Google Scholar
• Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opin Pharmacother 2010;11:919-28
   PubMed Web of Science ®Google Scholar
• Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect 2011;17:122-34
   PubMed Web of Science ®Google Scholar
• Approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). U.S. Food and Drug Administration (FDA). 2011. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm [Last accessed 27 March 2013]
   Google Scholar
• Approval of Victrelis (boceprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV). U.S. Food and Drug Administration (FDA). 2011. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm255413.htm [Last accessed 27 March 2013]
   Google Scholar
• Pockros P, Jensen D, Tsai N, et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial [abstract 1359]. J Hepatol 2011;54:S538
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) ± peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study [abstract 81]. Hepatology 2012;56:231A-2A
   Web of Science ®Google Scholar
• Larrey D, Lohse AW, De Ledinghen V, et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012;57:39-46
   PubMed Web of Science ®Google Scholar
• Soriano V, Gane EJ, Angus PW, et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335 + BI 207127 ± ribavirin (RBV) in treatment-naïve patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: results from the SOUND-C2 study [abstract 84]. Hepatology 2012;56:234A
   Web of Science ®Google Scholar
• Lawitz E, Lalezari JP, Hassanein T, et al. Once-daily PSI-7977 plus peg/RBV in treatment-naive patients with HCV GT1: robust end of treatment response rates are sustained post-treatment [abstract 225]. Hepatology 2011;54:472A-3A
   PubMed Web of Science ®Google Scholar
• Hassanein T, Lawitz E, Crespo I, et al. Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naïve patients with HCV genotype 1, 4, and 6 infection in the ATOMIC study [abstract 230]. Hepatology 2012;56:307A
   Web of Science ®Google Scholar
• Pol S, Ghalib RH, Rustgi VK, et al. First report of SVR12 for a NS5A replication complex inhibitor BMS-790052 in combination with PEG-IFNa-2A and RBV: phase 2A trial in treatment-naïve HCV-genotype-1 subjects [abstract 1373]. J Hepatol 2011;54:S544-5
   Web of Science ®Google Scholar
• Garg V, Van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-7
   PubMed Web of Science ®Google Scholar
• Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002;2:675-87
   PubMed Web of Science ®Google Scholar
• Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010;59:1279-87
   PubMed Web of Science ®Google Scholar
• Barth H, Schafer C, Adah MI, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003;278:41003-12
   PubMed Web of Science ®Google Scholar
• Barth H, Schnober EK, Zhang F, et al. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 2006;80:10579-90
   PubMed Web of Science ®Google Scholar
• Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766-71
   PubMed Web of Science ®Google Scholar
• Evans MJ, Von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-5
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011;54:566-76
   PubMed Web of Science ®Google Scholar
• Harris HJ, Farquhar MJ, Mee CJ, et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 2008;82:5007-20
   PubMed Web of Science ®Google Scholar
• Harris HJ, Davis C, Mullins JGL, et al. Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 2010;285:21092-102
   PubMed Web of Science ®Google Scholar
• Dao Thi VL, Granier C, Zeisel MB, et al. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem 2012;287:31242-57
   PubMed Web of Science ®Google Scholar
• Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011;17:589-95
   PubMed Web of Science ®Google Scholar
• Zona L, Lupberger J, Sidahmed-Adrar N, et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 2013;13:302-13
   PubMed Web of Science ®Google Scholar
• Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882-6
   PubMed Web of Science ®Google Scholar
• Sainz B Jr, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-Like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012;18:281-5
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR. HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS 2009;4:82-7
   PubMedGoogle Scholar
• Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011;17:1176-90
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 2008;48:299-307
   PubMedGoogle Scholar
• Fafi-Kremer S, Fauvelle C, Felmlee DJ, et al. Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses 2012;4:2016-30
   PubMed Web of Science ®Google Scholar
• Meuleman P, Bukh J, Verhoye L, et al. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011;53:755-62
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Baumert TF. HCV entry and neutralizing antibodies: lessons from viral variants. Future Microbiol 2009;4:511-17
   PubMed Web of Science ®Google Scholar
• Giang E, Dorner M, Prentoe JC, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 2012;109:6205-10
   PubMed Web of Science ®Google Scholar
• Davis GL, Nelson DR, Terrault N, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005;11:941-9
   PubMed Web of Science ®Google Scholar
• Schiano TD, Charlton M, Younossi Z, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006;12:1381-9
   PubMed Web of Science ®Google Scholar
• Davis GL. Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl 2006;12:1317-19
   PubMed Web of Science ®Google Scholar
• Fofana I, Fafi-Kremer S, Carolla P, et al. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 2012;143:223-233.e9
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol 2013;58:375-84
   PubMed Web of Science ®Google Scholar
• Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010;139:953-64.964; e1–4
   PubMed Web of Science ®Google Scholar
• Zahid MN, Turek M, Xiao F, et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 2013;57:492-504
   PubMed Web of Science ®Google Scholar
• Si Y, Liu S, Liu X, et al. A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology 2012;56:507-15
   PubMed Web of Science ®Google Scholar
• Syder AJ, Lee H, Zeisel MB, et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011;54:48-55
   PubMed Web of Science ®Google Scholar
• Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008;48:1761-8
   PubMed Web of Science ®Google Scholar
• Meuleman P, Catanese MT, Verhoye L, et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012;55:364-72
   PubMed Web of Science ®Google Scholar
• Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201
   PubMed Web of Science ®Google Scholar
• Flisiak R, Jaroszewicz J, Flisiak I, Łapiński T. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs 2012;21:375-82
   PubMed Web of Science ®Google Scholar
• Matsumura T, Hu Z, Kato T, et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 2009;137:673-81
   PubMed Web of Science ®Google Scholar
• Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009;90:1055-70
   PubMed Web of Science ®Google Scholar
• Vivès RR, Lortat-Jacob H, Fender P. Heparan sulphate proteoglycans and viral vectors: ally or foe? Curr Gene Ther 2006;6:35-44
   PubMed Web of Science ®Google Scholar
• Bernfield M, Götte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77
   PubMed Web of Science ®Google Scholar
• Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001;108:169-73
   PubMed Web of Science ®Google Scholar
• Krepstakies M, Lucifora J, Nagel CH, et al. A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis 2012;205:1654-64
   PubMed Web of Science ®Google Scholar
• Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One 2011;6:e23710
   PubMed Web of Science ®Google Scholar
• Penin F, Combet C, Germanidis G, et al. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 2001;75:5703-10
   PubMed Web of Science ®Google Scholar
• Jiang J, Cun W, Wu X, et al. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012;86:7256-67
   PubMed Web of Science ®Google Scholar
• Maillard P, Walic M, Meuleman P, et al. Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS One 2011;6:e26637
   PubMed Web of Science ®Google Scholar
• Koutsoudakis G, Kaul A, Steinmann E, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006;80:5308-20
   PubMed Web of Science ®Google Scholar
• De Haas CJ, Van der Zee R, Benaissa-Trouw B, et al. Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralize LPS. Infect Immun 1999;67:2790-6
   PubMed Web of Science ®Google Scholar
• Andrä J, Garidel P, Majerle A, et al. Biophysical characterization of the interaction of Limulus polyphemus endotoxin neutralizing protein with lipopolysaccharide. Eur J Biochem 2004;271:2037-46
   PubMedGoogle Scholar
• Andrä J, Howe J, Garidel P, et al. Mechanism of interaction of optimized Limulus-derived cyclic peptides with endotoxins: thermodynamic, biophysical and microbiological analysis. Biochem J 2007;406:297-307
   PubMed Web of Science ®Google Scholar
• Gutsmann T, Razquin-Olazarán I, Kowalski I, et al. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob Agents Chemother 2010;54:3817-24
   PubMed Web of Science ®Google Scholar
• Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003;197:633-42
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6
   PubMed Web of Science ®Google Scholar
• Brimacombe CL, Grove J, Meredith LW, et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011;85:596-605
   PubMed Web of Science ®Google Scholar
• Timpe JM, Stamataki Z, Jennings A, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008;47:17-24
   PubMed Web of Science ®Google Scholar
• Fox JL. Antivirals become a broader enterprise. Nat Biotechnol 2007;25:1395-402
   PubMed Web of Science ®Google Scholar
• Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-33
   PubMed Web of Science ®Google Scholar
• Barth H, Robinet E, Liang TJ, Baumert TF. Mouse models for the study of HCV infection and virus-host interactions. J Hepatol 2008;49:134-42
   PubMed Web of Science ®Google Scholar